As observed for many antiangiogenic drugs, particularly those targeting the VEGF/VEGFR pathway56,57, the occurrence of adaptive resistance and tumor regrowth due to the selective pressure exerted by an IL30-targeting therapy cannot be excluded. The gene discussed is KDR; the disease is neoplasm.